Skip to main content
. Author manuscript; available in PMC: 2021 Mar 22.
Published in final edited form as: Oncogene. 2020 Sep 22;39(43):6719–6732. doi: 10.1038/s41388-020-01463-0

Figure 1. MBIP is highly amplified in Lung Adenocarcinoma.

Figure 1.

(A) Oncoprint analysis in TCGA provisional LUAD dataset, showing genetic alterations in KRAS, TP53, MBIP and other metastatic drivers as identified in our previously reported in vivo gain of function screen [7, 9]. Amplifications (red), deletions (blue), mutations (green). (B) MBIP alteration frequency across cancer types in TGGA datasets. (C) Oncomine analysis of MBIP mRNA expression profile in lung adenocarcinoma data sets.